Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,843 across all filing types
Latest filing 2018-04-10 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
关于投资设立全资孙公司的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's investment to establish a wholly-owned subsidiary. It details the investment amount, the subsidiary's basic information, and the board's approval. There is no financial data, no report attached or referenced as published, and no mention of regulatory certifications or voting results. The content fits the category of a capital or financing update, as it concerns the company's capital allocation and investment activities rather than a full financial report or other categories.
2018-04-10 Chinese
理财产品管理制度（2018年4月）
Governance Information Classification · 95% confidence The document is titled '理财产品管理制度' which translates to 'Wealth Management Product Management System'. It is a detailed internal policy document outlining the principles, approval authorities, risk control, and management procedures for the company's investment in financial products. It includes references to regulatory compliance, internal controls, and approval workflows. There are no financial statements, earnings data, or shareholder meeting materials. The document is a governance or internal control policy rather than a financial report or announcement. It does not fit categories like Annual Report, Earnings Release, or Regulatory Filings. The content aligns best with Governance Information (CGR), which covers internal rules and governance practices of the company.
2018-04-10 Chinese
关于召开2017年度股东大会的提示性公告
AGM Information Classification · 95% confidence The document is a detailed announcement about the convening of the 2017 Annual General Meeting (AGM) of 普洛药业股份有限公司. It includes information about the meeting date, voting procedures (both in-person and online), agenda items to be discussed and voted on (such as the 2017 annual report, board and supervisory reports, financial report, profit distribution plan, and other proposals), registration details, and proxy voting instructions. The document does not contain the actual annual report or financial statements but rather serves as a notice and instructions for shareholders regarding the AGM. The document length is 4774 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting, including notices and voting instructions.
2018-04-03 Chinese
西南证券股份有限公司关于公司2017年度保荐工作报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2017年度保荐工作报告" which translates to "2017 Annual Sponsorship Work Report" by Southwest Securities Co., Ltd. regarding Puluo Pharmaceutical Co., Ltd. The content details the sponsorship work overview, including review of company disclosures, supervision of fundraising, governance oversight, and issues found with corrective measures. It also includes company and shareholder commitment fulfillment and other related matters. The document is a detailed report on the sponsorship activities and compliance monitoring for the year 2017, not a financial report like an annual or interim report, nor an announcement or certification. It is a specialized report related to sponsorship work, which aligns with the category of Audit Report / Information (AR) as it involves review, supervision, and audit-related activities but is not a full annual report (10-K) or earnings release. The length (7173 characters) and detailed content confirm it is a substantive report, not a brief announcement or certification. Therefore, the best fitting classification is AR (Audit Report / Information). FY 2017
2018-03-21 Chinese
西南证券股份有限公司关于公司2017年度定期现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2017年度定期现场检查报告" which translates to "2017 Annual Regular On-site Inspection Report". It is issued by a sponsoring institution (西南证券股份有限公司) regarding 普洛药业股份有限公司. The content includes detailed inspection items related to corporate governance, internal control, information disclosure, use of raised funds, performance, and other important matters. The document is a detailed report of an on-site inspection rather than a general annual report or financial statement. It does not contain financial statements or earnings data but focuses on compliance, governance, and internal control checks. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and results of regulatory inspections. The document length is 3392 characters, which is relatively short but contains substantive inspection content, not just an announcement or certification. Therefore, the best classification is AR with high confidence. FY 2017
2018-03-21 Chinese
关于收到公司高管辞职的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a company's senior executive (vice general manager). It includes details about the resignation, the effective date, and the executive's shareholding status. There is no financial data, report, or presentation content. The document fits the category of announcements about changes in senior management or board members.
2018-03-16 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.